LEAP 002, 2023 NCT03713593
pembrolizumab plus lenvatinib (n=395) vs. lenvatinib (n=399)
randomized controlled trial
lenvatinib in combination with pembrolizumab
lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks)
Lenvatinib
lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) placebo
mHCC - 1st line (L1)
double blind
172 sites
study Misses Primary End Points